Latest Derivatives News

Cynata Therapeutics is on the cusp of releasing critical data from its Phase 2 aGvHD and Phase 3 osteoarthritis trials in Q2 2026, while managing a tight cash runway and preparing for a capital raising.

Gold Hydrogen is poised to begin flow testing at its Ramsay Project, targeting separate Natural Hydrogen and Helium zones, while advancing green methanol and helium commercialisation studies amid robust market demand.

Osmond Resources is progressing its Orión EU Critical Minerals Project with promising drilling results, positive mineral processing testwork, and a new partnership targeting rare earth carbonate production in Spain.

Dateline Resources is poised to release its Colosseum Gold Project Bankable Feasibility Study imminently, while expanding rare earth exploration at its new Music Valley project and bolstering its balance sheet with a $50 million placement.

Neurotech International has opened its first Phase 3 clinical site for NTI164 targeting Autism Spectrum Disorder, reported positive 90-day toxicology results, and launched a new Rett syndrome research collaboration.

Anax Metals’ updated DFS for Whim Creek reveals a 113% surge in free cash flow to A$723 million, underpinned by a decade-long mine life and rapid payback. The company’s $10 million capital raise strengthens its balance sheet following full repayment of a $3.5 million loan.

Rokeby Resources bolsters its portfolio with the acquisition of the high-grade Omeo Gold Project in Victoria, while unveiling promising exploration results at its Queensland assets and planning a delayed drilling campaign. The company has secured $4 million in capital commitments and announced key leadership changes.

Enegex Limited has defined a large, shallow gold system at its Kalama Bave prospect in Côte d’Ivoire, with high-grade intercepts from aircore drilling and a new gold zone identified nearby. A $10.2 million capital raise supports ongoing exploration including a planned 3,000m RC program at Gogo.

Parkway Corporate Limited delivered a record $5.21 million quarterly revenue and $0.73 million EBITDA in Q3 FY26, driven by ramp-up of a major water infrastructure project. Meanwhile, its flagship Queensland Brine Management Complex progresses through key development application milestones with public notification underway.

Etherstack has smashed its first half revenue record for FY26 with strong government contract deliveries, prompting an upward revision of full-year revenue guidance to as much as US$18.9 million.

Vanadium Resources (ASX: VR8) has signed a non-binding offtake term sheet with U.S. Vanadium for 100% of vanadium slag from its Steelpoortdrift V-Iron Plant, while appointing Rand Merchant Bank to secure project financing.

Neuren Pharmaceuticals reported a solid A$30.4 million net profit in 2025, powered by a 15% rise in DAYBUE® royalties. The company is progressing its NNZ-2591 Phase 3 trial for Phelan-McDermid syndrome and has initiated a share buy-back amid perceived undervaluation.